Smoking and other determinants of bone turnover.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
05
2019
accepted:
04
11
2019
entrez:
26
11
2019
pubmed:
26
11
2019
medline:
24
3
2020
Statut:
epublish
Résumé
The balance between bone resorption and formation may be assessed by measurement of bone turnover markers (BTMs), like carboxyl-terminal cross-linked telopeptide of type 1 collagen (CTX-1) and procollagen type 1 amino-terminal propeptide (P1NP). Smoking has been shown to influence bone turnover and to reduce bone mass density (BMD), the exact mechanism for this is, however, not settled. In this post-hoc study including 406 subjects (mean age 51.9 years), we aimed to study the impact of smoking on bone turnover. Moreover, we wanted to assess the inter-correlation between substances regulating bone metabolism and BTMs, as well as tracking over time. BMD measurements and serum analyses of CTX-1, P1NP, osteoprotegerin (OPG), receptor activator of nuclear factor ĸB ligand (RANKL), Dickkopf-1 (DKK1), sclerostin, tumor necrosis factor-α (TNF-α), and leptin were performed. Repeated serum measurements were made in 195 subjects after four months. Adjustments were made for sex, age, body mass index (BMI), smoking status, insulin resistance, serum calcium, parathyroid hormone, 25-hydroxyvitamin D and creatinine. Smokers had higher levels of DKK1 and OPG, and lower levels of RANKL, as reflected in lower BTMs and BMD compared to non-smokers. There were strong and predominantly positive inter-correlations between BTMs and the other substances, and there was a high degree of tracking with Spearman's rho from 0.72 to 0.92 (P < 0.001) between measurements four months apart. In conclusion, smokers exhibited higher levels of DKK1 and OPG and a lower bone turnover than did non-smokers. The strong inter-correlations between the serum parameters illustrate the coupling between bone resorption and formation and crosstalk between cells.
Identifiants
pubmed: 31765401
doi: 10.1371/journal.pone.0225539
pii: PONE-D-19-14971
pmc: PMC6876776
doi:
Substances chimiques
Biomarkers
0
DKK1 protein, human
0
Intercellular Signaling Peptides and Proteins
0
Osteoprotegerin
0
Parathyroid Hormone
0
Peptide Fragments
0
Procollagen
0
RANK Ligand
0
procollagen Type I N-terminal peptide
0
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0225539Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Endocrinol Metab. 2014 Jan;99(1):315-21
pubmed: 24178795
Osteoporos Int. 2005 Feb;16(2):155-62
pubmed: 15175845
Epilepsy Res. 2013 Oct;106(3):417-22
pubmed: 23916144
Int J Environ Res Public Health. 2013 Dec 20;11(1):202-17
pubmed: 24452255
J Clin Endocrinol Metab. 2014 Jun;99(6):2155-63
pubmed: 24606073
Int J Obes Relat Metab Disord. 2003 Jan;27(1):88-94
pubmed: 12532159
Int J Psychophysiol. 2006 Mar;59(3):228-35
pubmed: 16337291
Biochem Pharmacol. 2008 May 15;75(10):2034-44
pubmed: 18396263
Am J Epidemiol. 2010 Apr 15;171(8):903-8
pubmed: 20219763
Metabolism. 2019 Feb;91:30-38
pubmed: 30412696
Int J Endocrinol. 2017;2017:8724869
pubmed: 28255300
Am J Pathol. 2006 Dec;169(6):2236-44
pubmed: 17148684
Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):325-8
pubmed: 16101541
J Bone Metab. 2014 Aug;21(3):163-7
pubmed: 25247154
Nat Med. 2013 Mar;19(3):358-63
pubmed: 23396210
J Clin Endocrinol Metab. 2010 Apr;95(4):1690-8
pubmed: 20194709
J Diabetes Res. 2017;2017:9021314
pubmed: 28695134
Bone. 2002 Jan;30(1):307-13
pubmed: 11792602
PLoS One. 2013;8(3):e59402
pubmed: 23555029
Horm Metab Res. 2016 Nov;48(11):755-763
pubmed: 27871116
Osteoporos Int. 2011 Feb;22(2):391-420
pubmed: 21184054
Ann Agric Environ Med. 2017 May 11;24(2):181-184
pubmed: 28664690
Neuro Endocrinol Lett. 2010;31(1):155-60
pubmed: 20150868
Histochem Cell Biol. 2018 Apr;149(4):305-312
pubmed: 29435763
Osteoporos Int. 2012 Aug;23(8):2081-92
pubmed: 22349964
Obes Res. 1999 Mar;7(2):141-9
pubmed: 10102250
Int J Endocrinol. 2015;2015:967673
pubmed: 25873961
Kidney Int. 2000 Sep;58(3):1285-92
pubmed: 10972692
Am J Respir Crit Care Med. 2015 Mar 15;191(6):620-5
pubmed: 25581779
J Osteoporos. 2015;2015:174186
pubmed: 25874154
Nutr Metab (Lond). 2009 Jan 14;6:3
pubmed: 19144201
Int J Epidemiol. 2012 Aug;41(4):961-7
pubmed: 21422063
Clin Med Insights Endocrinol Diabetes. 2014 Jul 29;7:19-24
pubmed: 25125991
Child Obes. 2016 Jun;12(3):179-87
pubmed: 27027910
Open Access Maced J Med Sci. 2016 Jun 15;4(2):302-6
pubmed: 27335606
Int J Dent. 2016;2016:6296854
pubmed: 26989414
Calcif Tissue Int. 2019 Jun;104(6):599-604
pubmed: 30680432
Bone. 2019 Jul;124:7-13
pubmed: 30959189
Rev Endocr Metab Disord. 2015 Jun;16(2):131-9
pubmed: 25557611
J Bone Miner Res. 2014 Apr;29(4):787-95
pubmed: 24123088
J Intern Med. 2018 Feb;283(2):140-153
pubmed: 29265670
Scand J Clin Lab Invest. 2011 Jul;71(4):340-3
pubmed: 21486111
J Clin Endocrinol Metab. 2016 Aug;101(8):3222-30
pubmed: 27294326
J Bone Miner Res. 2001 Aug;16(8):1426-33
pubmed: 11499865
J Toxicol. 2018 Dec 23;2018:4854152
pubmed: 30675155
J Osteoporos. 2018 Dec 2;2018:1206235
pubmed: 30631414
Eur J Endocrinol. 2018 Jan;178(1):R19-R31
pubmed: 29046326
Bone Rep. 2017 Feb 16;6:51-59
pubmed: 28377982
J Clin Endocrinol Metab. 2012 Jan;97(1):148-54
pubmed: 21994959
Eur J Endocrinol. 2005 Jan;152(1):39-45
pubmed: 15762185
PLoS One. 2013;8(1):e54615
pubmed: 23349940
Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):43-9
pubmed: 15964536
Endocr Connect. 2018 Jun;7(6):840-849
pubmed: 29764903
Curr Osteoporos Rep. 2017 Jun;15(3):126-134
pubmed: 28477234
Int J Mol Sci. 2018 Dec 17;19(12):
pubmed: 30562925
Bone. 2017 Mar;96:29-37
pubmed: 27742498
Cell. 2010 Jul 23;142(2):296-308
pubmed: 20655470
Bone Rep. 2016 Apr 28;5:104-109
pubmed: 27795978